in this issue
Regions :: Western Europe :: Switzerland
Carbogen Amcis invests in ADC capabilities
12:09 AM MDT | October 3, 2013 | Deepti Ramesh
Carbogen Amcis (Bubendorf, Switzerland), a pharma process-development and active pharmaceutical ingredient (API) manufacturing subsidiary of Dishman Pharmaceuticals and Chemicals (Ahmedabad, India) says it is investing to enhance its antibody drug conjugate (ADC) capabilities in order to better respond to increasing demand for ADCs in the development of highly targeted cancer treatments. The investments include a $4-million clean room clinical supply facility at the Bubendorf site and nearly a $1-million upgrade of the sterile manufacturing area in the facility...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee